Shortage of oncology drugs is a particularly complicated issue because there are usually limited therapeutic options. Moreover, oncology practice may employ medications for supportive indications which differ from their main usage. This means shortage of oncology drugs is not usually addressed by the major drug shortage guidelines. We have previously shown that, during a shortage crisis, it is possible to make a recommendation on the use of an expired drug supply based on a reasonable estimate of its safety and efficacy. Here, we would like to share further examples on how to deduce potential therapeutic alternatives based on pharmacokinetic and pharmacodynamic principles in the absence of direct clinical evidence in the literature.
GatesmanMLSmithTJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med2011; 365: 1653–1655.
2.
LinkMPHagertyKKantarjianHM. Chemotherapy drug shortages in the United States: genesis and potential solutions. J Clin Oncol2012; 30: 692–694.
3.
BeckerDJTalwarSLevyBP. Impact of oncology drug shortages on patient therapy: unplanned treatment changes. J Oncol Pract2013; 9: e122–e128.
4.
JagsiRSpenceRRathmellWK. Ethical considerations for the clinical oncologist in an era of oncology drug shortages. Oncologist2014; 19: 186–192.
5.
McBrideAHolleLMWestendorfC. National survey on the effect of oncology drug shortages on cancer care. Am J Health-Syst Pharm2013; 70: 609–617.
6.
GogineniKShumanKLEmanuelEJ. Survey of oncologists about shortages of cancer drugs. N Engl J Med2013; 369: 2463–2464.
7.
GoldsackJCReillyCBushC. Impact of shortages of injectable oncology drugs on patient care. Am J Health-Syst Pharm2014; 71: 571–578.
8.
de LemosMKletasVManS. Using expired supply in times of drug shortage. J Oncol Pharm Pract2012; 18: 319–319.
9.
Bristol-Myers Squibb Pharmaceutical Group and Divison of Bristol-Myers Canada Inc. TAXOL® product monograph, Montreal, Canada, 2006.
10.
MarkmanMKennedyAWebsterK. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions. J Cancer Res Clin Oncol1999; 125: 427–429.
11.
MarkmanMKennedyAWebsterK. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland clinic cancer center. J Clin Oncol2000; 18: 102–105.
12.
LenzHJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist2007; 12: 601–609.
13.
Morichau-BeauchantMHouinGMavierP. Pharmacokinetics and bioavailability of ranitidine in normal subjects and cirrhotic patients. Dig Dis Sci1986; 31: 113–118.
Eli Lilly Canada Inc. ALIMTA® product monograph, Toronto, Ontario, 2013.
16.
BunnPPaolettiPNiyikizaC. Vitamin B12 and folate reduce toxicity of ALIMTA (pemetrexed disodium, LY231514, MTA), a novel antifolate/antimetabolite. Proc Am Soc Clin Oncol2001; 20: 76a–76a.
17.
NiyikizaCBakerSDSeitzDE. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther2002; 1: 545–552.
18.
ScagliottiGVParikhPvon PawelJ. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol2008; 26: 3543–3551.
19.
ScagliottiGVShinDKindlerHL. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol2003; 21: 1556–1561.
20.
KuzminskiAMDel GiaccoEJAllenRH. Effective treatment of cobalamin deficiency with oral cobalamin. Blood1998; 92: 1191–1198.
21.
EussenSJde GrootLCJoostenLW. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr2006; 84: 361–370.
22.
FavratBVaucherPHerzigL. Oral vitamin B12 for patients suspected of subtle cobalamin deficiency: a multicentre pragmatic randomised controlled trial. BMC Fam Pract2011; 12: 2–2.
23.
SealECMetzJFlickerL. A randomized, double-blind, placebo-controlled study of oral vitamin B12 supplementation in older patients with subnormal or borderline serum vitamin B12 concentrations. J Am Geriatr Soc2002; 50: 146–151.
24.
SharabiACohenESulkesJ. Replacement therapy for vitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol2003; 56: 635–638.
25.
AndresEKurtzJEPerrinAE. Oral cobalamin therapy for the treatment of patients with food-cobalamin malabsorption. Am J Med2001; 111: 126–129.
26.
BolamanZKadikoyluGYukselenV. Oral versus intramuscular cobalamin treatment in megaloblastic anemia: a single-center, prospective, randomized, open-label study. Clin Ther2003; 25: 3124–3134.
27.
Guidelines and Protocols Committee. Cobalamin (vitamin B12) deficiency: investigation and management. Medical Services Commission, British Columbia Ministry of Health, 1 May 2013, www.bcguidelines.ca/guideline_cobalamin.html (accessed 10 January 2014).
28.
GreenhalghTHowickJMaskreyN. Evidence based medicine: a movement in crisis?BMJ2014; 348: g3725–g3725.
29.
SackettDLRosenbergWMGrayJA. Evidence based medicine: what it is and what it isn't. BMJ1996; 312: 71–72.
30.
GuyattGHOxmanADVistGE. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008; 336: 924–926.
